In this episode with the Good CME Practice group (gCMEp), Katie Eustace (Answers in CME) and Carry Pesch (Medcon International) are in conversation with Melanie Fleeman (Bayer) and Nefeli Georgoulia (AstraZeneca) about key strategic considerations about CME/IME within the medical affairs team in pharma.

gCMEp is a membership organisation for CME providers based in Europe that aims to promote professionalism within the European CME provider community. More information on the gCMEp can be found on the journal website: gCMEp.org.

Tune in to learn more about how to overcome challenges in IME/CME outcomes.

On today’s episode you will hear about:

- How important is IME/CME to pharma and why 

- Where can IME/CME be aligned to add value to medical affairs strategy

- How are data from outcomes used internally to demonstrate value

- How is the budget for IME/CME aligned within medical affairs strategy and what are the primary factors that influence internal decisions for budget allocation

- What evidence or information helps elevate conversations internally for IME/CME activities